A unique platform portfolio
A proprietary portfolio of small molecules and core structures serving as unique target discovery tools and starting points for designing therapeutics.
First-in-class programs
A growing portfolio of patient-focused programs that meet and surpass standards of care in models of critical underserved disease.
Our purpose
SHY’s priorities are set by the benefits we believe our work can ultimately deliver for significantly ill patients. We are here to generate clinically and scientifically significant results – not biobucks, biotech bravado, or false hopes.
We will measure our success by the therapeutics we develop; the contributions we make to basic science and medical innovation; and our balanced fulfillment of the expectations of patients, clinicians, shareholders, and other stakeholders.
Our strategic approach
SHY’s strategy is to focus on the discovery and early clinical stage development of impactful, valuably differentiated therapeutic programs and intellectual property derived from our novel pharmacophore and compound portfolio. We are an intentionally lean, focused company. We conduct critical in vitro and in vivo experiments in our laboratories on the campus of the New York Medical College. We outsource other activities to collaborators including pharmacokinetic studies, medicinal chemistry, and compound synthesis and scale-up.
SHY welcomes collaborations with similarly-minded scientists and clinicians. We anticipate undertaking late-stage clinical development and product commercialization with experienced pharmaceutical and biotechnology partner companies.
SHY's unique molecule portfolio enables us to target ATPases and GTPases associated with serious unmet medical needs and to identify and address new treatment targets.
Our compounds show promising preclinical efficacy and tolerability, matching or surpassing current treatment standards in cancer and infectious disease models.
To date, no single company has focused on targeting ATPases and GTPases, creating a groundbreaking path for innovation.
SHY’s novel compound portfolio is based on machine learning analyses of traditional and in-silico libraries, proprietary screens and inspired structure activity relationship (SAR) processes.
Our success in developing potential therapeutics stems from our ability to leverage this novel compound portfolio as both a foundation for developing small molecule therapeutics and as a target discovery tool.
Developing small molecule therapeutics that non-covalently target ATPases and GTPases
ATPases and GTPases are proteins central to the development of many serious diseases. SHY’s portfolio of small molecules are designed to hit a class of targets - both ATPases and GTPases - with high specificity and wide therapeutic windows.